Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03902353
Other study ID # K180501J
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 23, 2019
Est. completion date September 1, 2021

Study information

Verified date July 2019
Source Assistance Publique - Hôpitaux de Paris
Contact MONTANI David, PhD
Phone 01.45.21.79.76
Email david.montani@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pulmonary Veino Occlusive Disease (PVOD) is a rare form of pulmonary arterial hypertension, characterised by a poor prognosis. Recent studies demonstrated that heritable form of pulmonary veino occlusive diseaseis due to bi-allelic mutations in EIF2AK4 gene. heritable pulmonary veino occlusive disease is an autosomal recessive disease. In the french referal center of severe PH, ulmonary veino occlusive disease patients carriers of bi-allelic mutations in EIF2AK4 gene were identified. Genetic counselling in these families allowed to identified herozygous carriers of a single mutation in EIF2AK4 gene. However, to date, nothing is known about the risk of these persons of developping pulmonary diseases. It appears essential to determine the clinical, functional, echocardiographic and radiologics characteristics of these persons, and their risk of developping Pulmonary veino occlusive disease


Description:

the investigators will evaluate the subjects at inclusion after informed by a clinical evaluation (dyspnea assessed by New York Heart Association functional class (I-IV), signs of right heart failure), a 6min walk test, a Computerized Tomography scan of the chest, an electrocardiogram, an echocardiography , an abdomina ulstrasound, a Cardiopulmonary exercise testing, a lung function tests , arterial blood gases.

At one and two years, a phone call will be made to to participants evaluate dyspnea and intercurrent events in all subjects. In the presence of pulmonary veino occlusive diseaseis symptoms, a new evaluation will be proposed in order to confirm of not pulmonary veino occlusive diseaseis.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date September 1, 2021
Est. primary completion date September 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female adult (age =18 years of age at the date of inclusion),

- With an identification of the presence of a mutation of the EIF2AK4 gene in the heterozygous state,

- Having given free and informed consent.

Exclusion Criteria:

- Minor (age <18 years),

- Patient with known Pulmonary veino occlusive disease or Pulmonary arterial hypertension

- Woman having started a pregnancy or breastfeeding

- protected adult persons,

- Persons deprived of their liberty,

- People in emergency,

- Those who refused or were unable to give informed consent,

- Contraindication to the exercise test (acute coronary syndrome, syncope, tight stenotic valve disease ...) See the list of relative and absolute contraindications to the exercise test (chapter 6.2).

- No affiliation to a social security scheme (beneficiary or beneficiary).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Screening of adult without diagnosis of PH carrying an heterozygous EIF2AK4 mutation.
will be performed : a clinical evaluation (dyspnea assessed by New York Heart Association functional class (I-IV), signs of right heart failure), a 6min walk test, a Computerized Tomography scan of the chest, an electrocardiogram, an echocardiography (measurement of the velocity of tricuspid regurgitation, measurement of Tricuspid Annular Plane Systolic Excursion (TAPSE) and Tei index, pericardial effusion, dilatation and hypertrophy of the right ventricle), an abdomina ulstrasound, a stress Test (ventilation oxygen peak and ventilation oxygen specific, minute ventilation, dead-space ventilation / dead space, ventilatory reserve, alveolar-arterial gradient, pulse oxygen, PaO2), a lung function tests and measurement of Diffusing capacity or transfer factor of the Lung for Carbon mOnoxide (DLCO) and Nitric Oxide (DLNO), and a blood sample.

Locations

Country Name City State
France David MONTANI Le Kremlin-Bicêtre Krémlin Bicêtre

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evolution of characteristics of asymptomatic heterozyous EIF2AK4 mutation carriers and monitor these subjects' clinical, functional, biological, echocardiographic frequency of abnormalities observed 1 year
Secondary predictive factors of the occurrence of PVOD follow prospectively a cohort of asymptomatic heterozyous EIF2AK4 mutation carriers to determine predictive factors of the occurrence of VOD number of heterozygous EIF2AK4 mutation carriers who will develop Pulmonary Veno-Occlusive Disease 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03246841 - Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes. N/A
Completed NCT04068961 - New Strategies of Genetic Study of Patients With Oculocutaneous Albinism
Recruiting NCT05954442 - Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype Phase 3
Active, not recruiting NCT03857594 - Integrative Sequencing In Germline and Hereditary Tumours
Active, not recruiting NCT04983628 - Molecular Profiling in Prostate Cancer
Recruiting NCT05446155 - BioMEL- Diagnostic and Prognostic Factors in Melanoma.
Completed NCT02612350 - Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease
Recruiting NCT05311709 - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities Phase 2
Completed NCT02884063 - Utilizing Free DNA in Embryo Culture for PGT
Completed NCT02808715 - Identification and Metabolic Characterization of a Cohort of Human Subjects With Mutations in PRDM-16 N/A
Recruiting NCT05848271 - Natural History Study of Patients With HPDL Mutations
Enrolling by invitation NCT04708639 - Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients
Recruiting NCT03125759 - The Association of Omentin and Ischemic Stroke N/A
Recruiting NCT05162508 - Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease
Recruiting NCT03786575 - Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer N/A
Completed NCT05864937 - C677T Methylenetetrahydrofolate Reductase Mutation
Recruiting NCT03702309 - Liquid Biopsy Evaluation and Repository Development at Princess Margaret